Research Keyword: EORTC-MSGERC criteria

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study

mycolabadmin

This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.

Read More »

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19 infection, a fungal marker called beta-D-glucan (BDG) in the blood can predict patient survival even without a diagnosed fungal infection. Researchers found that COVID-19 patients with high BDG levels had a 91% death rate if not treated with antifungal drugs, but this dropped to 50% when antifungal therapy was given. The high BDG levels trigger a strong inflammatory response in the body that worsens disease severity, making BDG a valuable warning sign for doctors treating critically ill COVID-19 patients.

Read More »

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied 234 multiple myeloma patients who received a cutting-edge cancer treatment called BCMA CAR-T therapy. While this therapy can cause serious side effects related to immune system activation, the study found that dangerous fungal infections were surprisingly rare, occurring in only 1.7% of patients. However, when fungal infections did occur in these patients, they tended to be severe and life-threatening, highlighting the need for careful monitoring of high-risk patients.

Read More »
Scroll to Top